-
01.30.2025 | Nowe finansowanie dla terapii CMTX-101 – nadzieja na skuteczniejsze leczenie infekcji płuc w mukowiscydozie
Firma Clarametyx Biosciences, specjalizująca się w innowacyjnych terapiach przeciwbakteryjnych, otrzymała wsparcie finansowe od funduszu Kineticos AMR Accelerator Fund (KAMRA Fund).
-
01.30.2025 | Clarametyx Biosciences receives investment from Kineticos AMR Accelerator Fund
Clarametyx Biosciences, a Columbus, OH-based clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, received an investment from Kinetics AMR Accelerator Fund.
-
01.29.2025 | Neues Antibiotikum wird in Gießen entwickelt
Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950 000 Euro von der Initiative CARB-X.
-
01.29.2025 | Gießen im Kampf gegen Resistenzen: Neues Antibiotikum in Entwicklung!
Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950.000 Euro von der Initiative CARB-X zur Entwicklung eines neuartigen Antibiotikums.
-
01.28.2025 | CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia
CARB-X will award Rhode Island Hospital at Brown University Health US$1M to demonstrate proof-of-concept of a polymerase chain reaction (PCR) approach informed by RNA sequencing to detect bacterial pneumonia directly from whole blood.
-
01.28.2025 | Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test
CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.
-
01.28.2025 | Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test
CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.
-
01.28.2025 | CARB-X funds development of novel pneumonia diagnostic
CARB-X announced today that it is awarding $1 million to Rhode Island Hospital at Brown University Health to develop a test to diagnose bacterial pneumonia from whole blood.
-
01.23.2025 | Vedanta Biosciences publishes additional phase 2 VE303 results in Nature Medicine
BIOSPACE | VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms. Analyses identified predictors of VE303 colonization and protection from CDI recurrence. Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026.
-
01.23.2025 | CARB-X funds development of monoclonal antibody for Staph aureus
CIDRAP | CARB-X announced today that it is awarding $729,000 to Chicago-based biotechnology company Immunartes to develop a monoclonal antibody designed to prevent Staphylococcus aureus infections.
-
01.23.2025 | Debiopharm et GARDP signent un accord pour lutter contre l’antibiorésistance
LE TEMPS | L’entreprise pharmaceutique vaudoise et l’organisation basée à Genève ont annoncé un partenariat pour soutenir le développement d’un nouvel antibiotique contre la gonorrhée.
-
01.21.2025 | Mehr Geld für Antibiotikaforschung in Gießen
AERZTEBLATT | Die Justus-Liebig-Universität Gießen (JLU) erhält von der Initiative CARB-X rund 950.000 Euro in der ersten Förderrunde für die Entwicklung von Molekülen zur Hemmung eines spezifischen Proteins gramnegativer Bakterien.
-
01.17.2025 | CARB-X funds peptide antibiotic
CARB-X announced yesterday that it is awarding $610,000 to Justus Liebig University Giessen in Germany to develop a first-in-class peptide antibiotic.
-
01.15.2025 | Visby Medical secures additional $3.9M from CARB-X to fight antibiotic resistance with PCR-based mutation detection at the POC
Visby Medical, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from CARB-X to accelerate its fight against antibiotic resistance.
-
01.14.2025 | Nationwide Children’s spinoff targeting antibiotic resistance starts developing vaccine
A Nationwide Children's Hospital spinoff is developing a vaccine based on the same biotechnology it's testing as an antibody treatment attacking chronic drug-resistant infections.
-
01.14.2025 | Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae.
-
01.14.2025 | CARB-X grants Melio $3.5M for neonatal sepsis rest, Visby wins additional $3.9M
CARB-X announced Tuesday that it will fund diagnostics firm Melio $3.5 million to develop a rapid assay for the detection of neonatal sepsis. In a separate announcement on Wednesday, Visby Medical announced that it has received $3.9 million in additional funding from CARB-X to support its point-of-care gonorrhea assay using instrument-free PCR.
-
01.14.2025 | CARB-X funds rapid diagnostic test platform for bloodstream infections
CARB-X today announced an award of $3.5 million to biotechnology company Melio to develop a rapid diagnostic test for bloodstream infections, including neonatal sepsis.
-
01.14.2025 | CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
01.10.2025 | Peptilogics receives $3.3 million from CARB-X to develop treatment for fracture-related infections
CARB-X yesterday announced an award of $3.3 million to Pittsburgh-based Peptilogics to develop a slow-release version of its investigational, broad-spectrum therapeutic for joint-related infections.
-
01.09.2025 | CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
01.09.2025 | Seres Therapeutics announces new translational biomarker results from SER-155 Phase 1b clinical study and provides corporate updates
Seres Therapeutics, a leading live biotherapeutics company, today announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation (allo-HSCT).
-
01.08.2025 | Basilea provides portfolio update and outlook
Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones.